Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tau PET Binding in PPA and FTD
NCT02736695Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2016
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of flortaucipir (2 arms), sponsored by Mayo Clinic. Primary endpoint: Proportion of PPA Subjects That Showed Elevated Tau PET Binding Compared to Normal Controls at 1 week. Started Jul 2016; status: completed.
02
Drugs
flortaucipir
Beyond the preview
Go deeper on NCT02736695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736695.